Abstract
The prognosis of advanced non-small cell lung cancer (NSCLC) has been significantly improving ever since the discovery of oncogenic driver alterations and the implementation of targeted therapies. Today, molecular profiling, preferably by using next-generation sequencing panels as well as liquid biopsies is crucial before starting treatment in patients with non-squamous NSCLC independent of their smoking status, as well as in those with squamous NSCLC who are little or non-smokers. In this review, we present the latest evidence on the most detected driver alterations in advanced NSCLC apart from EGFR, B-RAF, ALK and ROS1. A few of the novel therapies have been approved in Europe in specific settings, and many are still not reimbursed by third-party payers. This highlights the importance of encouraging patients to participate in clinical trials to gain access to innovative treatments. Translational research programs are also important to uncover mechanisms of resistance to targeted therapies and how to overcome them.1877-1203/© 2022 SPLF. Published by Elsevier Masson SAS. All rights reserved.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
